Athena Athena

X
[{"orgOrder":0,"company":"DTx Pharma","sponsor":"Alzheimer's Association","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"DTx Pharma Receives Prestigious Funding Award to Support Research in Neurodegenerative Diseases of the CNS","therapeuticArea":"Neurology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Preclinical"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"RA Capital Management","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"DTx Pharma Completes $100M Series B Financing to Advance its FALCON\u2122 Platform and Pipeline of RNA Therapeutics","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DTx Pharma Receives FDA Orphan Drug Designation for DTx-1252 for the Treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"},{"orgOrder":0,"company":"DTx Pharma","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"$500.0 million","newsHeadline":"DTx Pharma Announces Acquisition by Novartis","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Genetic Disease","graph2":"IND Enabling"}]

Find Clinical Drug Pipeline Developments & Deals by DTx Pharma

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Through the acquisition, Novartis will accelerate the development of DTx-1252, a novel, potential first-in-class, FALCON siRNA candidate targeting PMP22, for the treatment of Charcot-Marie-Tooth Disease Type 1A (CMT1A).

            Lead Product(s): DTx-1252

            Therapeutic Area: Genetic Disease Product Name: DTx-1252

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation

            Deal Size: $1,000.0 million Upfront Cash: $500.0 million

            Deal Type: Acquisition July 17, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            DTx-1252 is a potential first-in-class FALCON™ siRNA therapeutic for treatment of CMT1A. By repressing PMP22, DTx-1252 reverses CMT1A in a mouse model that faithfully recapitulates the genetic and clinical manifestations of the disease.

            Lead Product(s): DTx-1252

            Therapeutic Area: Genetic Disease Product Name: DTx-1252

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 07, 2023

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Proceeds from the financing will be used to advance DTx’s pipeline utilizing its novel FALCON (Fatty Acid Ligand Conjugated OligoNucleotide) platform technology.

            Lead Product(s): RNA-based therapeutics

            Therapeutic Area: Genetic Disease Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Large molecule

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing March 01, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The award, along with prior and pending grants, will enable DTx to expand the application of its lipid conjugate technology for the delivery of oligonucleotides as potential treatment for neurodegenerative diseases.

            Lead Product(s): siRNAs

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Alzheimer's Association

            Deal Size: $0.4 million Upfront Cash: Undisclosed

            Deal Type: Funding May 13, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY